Undertreated and Deadly Coleman Foundation Winter Workshop February 28 2013 Andrea Bial MD Joanna Martin MD Objectives Learning Objectives 1 Understand how to recognize delirium in the hospice and palliative setting ID: 643663
Download Presentation The PPT/PDF document "Delirium: Underrecognized" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Delirium: Underrecognized, Undertreated and Deadly
Coleman Foundation Winter Workshop
February 28, 2013
Andrea
Bial
, MD
Joanna Martin, MDSlide2
ObjectivesLearning Objectives
1.
Understand how to recognize delirium in the hospice and palliative setting.
2.
Be
able to identify possible factors contributing to patients’ delirium.
3.
Incorporate best evidenced-based medicine in treating delirium in hospice and palliative care settings.
Content Bullets
1.
Recognize agitation, confusion, altered level of consciousness, hallucinations, restlessness and other behaviors associated with delirium in patients with advanced chronic illness.
2.
Understand when to pursue reversible causes of delirium and when to forgo evaluation and focus on comfort.
3. Be
able to use both pharmacological and
nonpharmacological
interventions to treat delirium in patients with advanced
chronic illness.Slide3
Delirium: What’s Going On?Pathophysiology not well understood
Thought to be deficit of acetylcholine (e.g., anticholinergic drugs as precipitant) and/or excess of dopamine (that’s why levodopa can cause & Haldol can help)
Other neurotransmitters (GABA, serotonin, norepinephrine, melatonin, others) and cytokines may also be involved.
Inouye 2006; Irwin 2013Slide4
Delirium: Prevalence~¼ to ½ of advanced cancer patients admitted to the hospital have delirium.
85-90% of all patients experience delirium in the hours or days before death.
Very
common in hospitalized older
patients
33% presenting to ER
14-24% on admission
15-53% post op
70-87% ICU
Inouye 2006;LeGrand 2012; White 2007Slide5
Delirium: Prevalence in Palliative Care
2013 Literature Review in
Palliative Medicine:
13-42% prevalence at admission to palliative or hospice units
26-62% prevalence at some point during hospitalization (in palliative or hospice unit)Slide6
Delirium: Outcomes Increased hospitalized mortality (25-75%)
Increased 1-year mortality (40%)
Increased LOS (2x)
Increased hospital complications (incontinence, falls, pressure sores)
Increased institutionalization (2-3x)
Increased healthcare costs (STAT)
Irwin2013Slide7
Delirium: Recognition Early identification of risk factors can reduce occurrence.
Early recognition of delirium can reduce duration (and potentially identify causative/contributing factors).
FOR LEARNERS:
Lecture format adequate for knowledge about delirium, but not to change provider behavior or improve outcomes.
Need interactive sessions and leaders using clinical pathways and assessment tools.
Inouye1993, Yanamadala2013Slide8
Why is delirium overlooked?Fluctuating natureOverlaps with dementia
Lack of formal cognitive assessment
Under appreciation of clinical consequences
Not considering the clinical diagnosis importantSlide9
Types of DeliriumHyperactive: “Agitated;” repeated (purposeless) limb movements, restless, trying to get out of bed, hallucinations,….
Hypoactive
Quite, withdrawn; may give monosyllabic answers to simple questions, follow simple commands
MixedSlide10
Predisposing Risk Factors
UPON ADMISSION
Serious illness (advanced cancer, sepsis, acute kidney failure,…)
Cognitive impairment
Vision impairment
Elderly
AFTER ADMISSION
Physical restraints
≥3 medications added
Malnourished
Urinary catheter placed
Inouye1993;1996;1999Slide11
An Ounce of Prevention…Yale Delirium Prevention Trial :
Orientation for cognitive impairment
Early mobilization
Prevention of sleep deprivation/fragmentation
Address vision & hearing impairments
Preventing dehydration
Inouye 1999Slide12
OverlookedInconsistent use of terminology (“confused, altered mental status agitated, lethargic,…”)
O
bjective testing rarely done
Confused with depression or dementia (see next slide)
Increase the risk of being overlooked:
Hypoactive form
Fluctuating symptoms
Age ≥80yrs
del Fabbro2006Slide13Slide14
Identifying DeliriumSeveral tools available
Confusion Assessment Method (CAM) (94-95%
sens
/spec)
Delirium Rating Scale
Delirium Symptom Interview
Memorial Delirium Assessment Scale
Casarett2001Slide15
CAM
I
nattentive
AND
A
cute
Onset w/ Fluctuating Course
AND
D
isorganized
Thinking AND/OR
Altered
L
evel of
Consciousness
HAVE TO HAVE #1 & #2 AND THEN #3 AND/OR #4 for positive screen.
HINT: IADL
Inouye1990Slide16
CAM: example questions
Inattentive: repeat numbers, days of week/months of the year backwards OR observe staring into space, not keeping track of conversation, etc.
Acute/fluctuating: ask
pt
about confusion OR observe variations in attention, speech, thinking, or
pyschomotor
activity. (can also ask RN or family)
Disorganized thinking: what type of place is this, why are you here, see or hear anything unusual? OR observe if
pt
disoriented or uses illogical ideas/inappropriate words/rambling conversation.
Altered Level of Consciousness: falling asleep during interview,
stuporous
/comatose, non-communicative?
Huang2012Slide17
Evaluation (after Identification)
In hospitalized patients:
History (does
pt
have dementia? What has been the time course?)
Physical Exam (new wounds, neurologic deficits, urinary or fecal retention, new
fx
,…?)
Laboratory Tests (if none recent:
wbc
,
cmp
, TSH, B12?)
Radiology Tests (CXR, head CT,….?)
In palliative (Advanced, Chronically ill) patients, is this terminal restlessness?
Inouye2006Slide18Slide19
Palliative Patients Irwin2013Slide20
Evaluation in Palliative Patients
Need to address Goals of
Care as it will guid
e extent of evaluation.
Easily addressed: constipation, urinary retention, medication side
effect, dehydration
More likely to be reversible in younger patients, those without organ failure, and those w/ less cognitive disturbance.
May be shorter time until death in those w/ irreversible
delrium
.
Leonard2008Slide21
Delirium=SyndromeDelirium is almost always multifactorial
Need to identify potential causes
Evaluation and treatment is always dependent on GOC Slide22
Causes of DeliriumMedications
New drug
Dose too high
In withdrawal (e.g., benzodiazepines
, psych drugs…)
Infection
Dehydration
Metabolic Abnormalities
Irwin2013;LeGrand2012Slide23
Additional Potential Causes of Delirium in CA pts
All of preceding causes, but also…
Primary or Secondary CNS tumors
Toxicity of antineoplastic therapies (chemo,
xrt
,…)
Toxicity of other drugs used in treatment (steroids, anti-nausea drugs, anticonvulsants,…)
Paraneoplastic
neurological syndromes
Caraceni2005Slide24
Treatment: Underlying CauseAdjust medication (if able)
Any medication that has CNS
s.e.
can contribute to delirium (especially those w/ hi anticholinergic activity)
See next slide
Treat infection
Address dehydration (IV fluids,
sq
fluids, oral hydration)
Consider fixing electrolyte abnormalitiesSlide25
Medications as Cause
Antibiotics
Steroids
Benadryl NSAIDS
Benzos
H2
Blockers
Digoxin
Parkinson’s
drugs
GI (
Reglan,
Bentyl
)
Tricyclics
Lithium
Narcotics
Neuroleptics
Any drug with
anticholinergic properties!Slide26
Treatment: NonpharmacologicSafety of room (minimize bed rails or pad, lower bed, mats on floor)
Reorientation (verbal cues, date boards, shades up)
Reduce restraints (“official” and “unofficial”)
Family/friends at bedside
Supply glasses or hearing aids if appropriateSlide27
Treatment: Pharmacologic Caveats
NO MEDICATIONS are currently approved by the FDA for management of delirium
NO published DB, RCT to guide medication management of delirium.
NO consensus: oncology, geriatrics, psychiatry, palliative medicine
Goal is to maximize safetySlide28
Treatment: PharmacologicHaloperidol as first drug of choice
Can be given IV, IM, SC, PO (pill or liquid)
LOW dose to start (0.5mg IV Q6H prn)
BEWARE EPIC!
Can repeat at 30mins if needed
Irwin2013;LeGrand2012Slide29
HaloperidolOld, cheap, decades of useRecent trial: 14 centers/4 countries/119 patients w/ delirium in hospice or palliative care:
Average daily dose: 2.1mg
Most frequent
s.e.
: somnolence (9%) & urinary retention (5%)
1/3 had net benefit (NCI delirium score)
Risks present with ALL antipsychotics
Black box warning on all: increased CV or infectious mx when used in dementia-related psychosis
Crawford2013, Irwin2013Slide30
Other Pharmacologic TreatmentsOther antipsychotics CAN be used
C
onsider side effects: potentially WANT more sedation, or weight gain, or other effect
May use if higher doses needed.
Benzodiazepines
C
an worsen delirium
Use as first-line only if alcohol/
benzo
withdrawal or having seizures
Can use as second line (in addition to Haldol) if not achieving adequate responseSlide31
Delirium in the ICUEstimates range from ~20-90% of patients
10% increase mx for each day of delirium
Additional risk factors:
Coma
Sedatives
Neurologic diagnosis
Reade2014Slide32Slide33
Terminal deliriumOften referred to as “terminal restlessness”
Characterized by agitation, repeated nonsensical requests (“I need to sit up”), repetitive movements, picking at clothes and sheets.
Occurs in up to 85% of patients in the last weeks of life
Family/caregiver education is key
Can use H
aldol
first line for symptom management
Consider use of benzodiazepines if
H
aldol ineffective,
especially in younger patientsSlide34
Terminal delirium: Family Support
The experience of delirium for families can complicate
bereavement
“
Double loss”
Grief when they lose ability to communicate meaningfully with patient and again when the patient dies
Although previous care may have been excellent, if the delirium goes misdiagnosed or unmanaged, family members may remember a horrible death "in terrible pain”Slide35
Terminal Delirium: Family Support, contd.
Families may be ambivalent about medication use: want the
pt
to be comfortable, but fear lack of communication w/
pt
or worry that death is hastened.
Families should be given ample opportunities to ask questions; information may need to be repeated.
If suspect death is near, important to ask family if they want to know prognostic information.
Brajtman2005Slide36
Patient AB105yo W in hospice w/ dementia and COPD.
Takes Xanax 0.25mg QHS (for years).
Called by RN:
pt
had a night of agitation: was up all night, convinced her son was being held hostage. When son was called to talk to her to reassure her he was ok, she was sure he was being forced to say he was fine.
CG couldn’t give her any more Xanax (
pt
refused) and family didn’t want to give her Haldol since last time she got it, “She was knocked out.”Slide37
Patient AB: QuestionsIs this patient delirious?Is this patient having terminal restlessness?
What do you recommend for the future?
Increase bedtime Xanax
Repeat bedtime Xanax dose at start of agitation
Use Haldol anyway
Have son come over and sit w/ patientSlide38
Patient ABWhat do you do?
Increase bedtime
Xanax to 0.5mg.
Repeat bedtime Xanax dose at start of
agitation.
Use Haldol
anyway, starting at lower dose than before and use at start of agitation.
Have son come over and sit w/
patient.
1., 2., 4.
1., 3.
None of the aboveSlide39
Patient case #1Mr. S is an 80 year old NH resident with history of end stage dementia admitted to hospice with history of aspiration pneumonia. Mr. S is usually calm, nonverbal and can sit in the dayroom in his wheelchair. The NH calls you that he
has become quite
agitated and won’t let the CNA give him his bath today.Slide40
Patient case #1 cont. . .NH reports patient usually calm and often sits in day room, pleasantly confused at baseline.
Exam: VSS with no BM since hospice admission one week ago, patient lying in bed, agitated and moaning, lung exam stable, abdomen distended with bowel sounds; rectal vault filled with stool
Meds reviewed: HCTZ, Nifedipine, prevacid, roxanol 5mg q4hrs prnSlide41
Is this patient delirious?Acute onset and fluctuating course YES
Inattention YES
Disorganized thinking NO
Altered level of consciousness YESSlide42
Patient case #1Patient is impacted
Fleets enema performed with good results
Patient straight cathed to check post void residual which was <100cc
Meds reviewed: HCTZ, nifedipine and roxanol can cause constipation
Meds adjusted
Bowel regimen: senna dailySlide43
Patient case #1Patient much more comfortable by the next day
He returns to baseline within a few days
Hospice team provides a lot of oversight to nursing home care; patient requires close medication monitoring and has ongoing issues with constipationSlide44
Patient case #2Patient is a 50 year old man with metastatic lung cancer admitted to hospice one month ago. Patient is steadily declining and using ativan now multiple times a day for anxiety. His wife contacts you that he is pacing, agitated and combative. At baseline he is usually anxious but can be reassured. Slide45
Case 2 continued. . . On exam, he is confused, hyperalert and report seeing ants walking on the ceiling. He is unable to follow your other questions. His exam is remarkable for cachexia and hypoxia. SOB is controlled. Bowels are moving and patient urinating regularly.
Meds: ativan (7 doses in past 24 hrs), decadron 4mg, MS Contin 30 bid and roxanol 5mg prnSlide46
Is this patient delirious?Acute onset and fluctuating course YES
Inattention YES
Disorganized thinking YES
Altered level of consciousness YESSlide47
Patient case #2Decision made to decrease dose of ativan back to bid and start haldol 0.5 mg bid and q4 hrs prn; give decadron in AM
Patient calms down enough to wear oxygen and wife able to manage sx
No need for opioid rotation
Ends up using haldol 1mg q4hrs ATC
Much calmer and comfortable until death one month laterSlide48
Patient case #2Decision made to decrease dose of ativan back to bid and start haldol 0.5 mg bid and q4 hrs prn; give decadron in AM
Patient calms down enough to wear oxygen and wife able to manage sx
No need for opioid rotation
Ends up using haldol 1mg q4hrs ATC
Much calmer and comfortable until death one month laterSlide49
Patient Case #3Patient is a 65 year old woman with stage IV breast cancer in home hospice
Family calls to report that patient more confused in past two days and sleeping moreSlide50
Case #3 continued. . . On exam: VSS, patient is sleepy and able to answer some questions but has trouble tracking conversation and is tangential, no focal neuro deficits noted, exam otherwise unchanged
Meds: fentanyl patch and roxanol prn; sennaSlide51
Is this patient delirious?Acute onset and fluctuating course YES
Inattention YES
Disorganized thinking YES
Altered level of consciousness YESSlide52
Patient case #3 continued. . .Patient with chronic severe pain so opioids not changed
Delirium likely due to final days of life
Family educated - KEY
Patient had some periods of lucidity over next several days and died
a week laterSlide53
Take Home PointsBe able to recognize signs and symptoms of delirium as early as
possible; remember hypoactive is the most common form and often not found unless looked for.
Assess for easily reversible causes of delirium and understand when evaluation is not indicated due to terminal restlessness/near EOL.
Be comfortable in using both pharmacological and
nonpharmacological
measures to treat delirium.
Provide information to family.Slide54
Works Cited
BrajtmanS
. Helping the family through the experience of terminal restlessness.
JHosPallNurs
2005;7:73.
CaraceniA
et al in Doyle D et al, eds. Oxford textbook of palliative medicine. OxfordUnivPress2005pp708-712
Cassarett
D et al. Diagnosis and management of delirium at end of life. Ann Intern Med 2001;135:32
Crawford GB et al.
Pharmacovigilance
in hospice/palliative care: net effect of haloperidol in delirium. J Pall Med. 2013;16:1335-1341.
Del
Fabbro
E et al. Symptom control in palliative care—part III: dyspnea and delirium. J Pall Med. 2006;9:422-433
.
Hosie
A et al. Delirium prevalence, incidence and implications for screening. Pall Med 2013;27:486.
Huang LW et al. Identifying indicators of important diagnostic features of delirium. JAGS 2012;60:1044-1050.
Irwin SA et al. Clarifying delirium management: practical, evidence based, expert recommendations for clinical practice. J Pall Med. 2013;16:423-435.
InouyeSK
et al. Clarifying Confusion: the confusion assessment model. AnnIntMed1990;113:941-948.
Inouye SK et al. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics. 1993;119:474-481.
Inouye SK et al. Precipitating factors for delirium in hospitalized elderly persons: predictive model and interrelationship with baseline vulnerability. JAMA1996;275:852-857
Inouye SK et al. A multicomponent intervention to prevent delirium in hospitalized older patients. NEJM 1999;340:669.
Inouye SK. Delirium in older persons. NEJM 2006;354:1157.
LeGrand
SB. Delirium in palliative medicine: a review.
JPainSymMan
2012;44:583-594
.
LeonardM
et al. Reversibility of
dellirium
in terminally ill patients & predictors of mortality. PallMed2008;22:848.
Reade MC, et al. Sedation and delirium in the ICU. NEJM 2014;370:444
Von
Gunten
CF et al. New versus old neuroleptics: efficacy versus marketing. J Pall Med 2013;16:1509-1514
.
White C et al. First do no harm…terminal restlessness or drug-induced delirium. J Pall Med 2007;10:345-351.
Yanamadala
M et al. Educational intervention to improve recognition of delirium: a systematic review. JAGS 2013;61:1983-1993.